<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60989">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311959</url>
  </required_header>
  <id_info>
    <org_study_id>14 SEIN 10</org_study_id>
    <nct_id>NCT02311959</nct_id>
  </id_info>
  <brief_title>Therapeutic Nipple Sparing Mastectomy.</brief_title>
  <acronym>MAPAM-01</acronym>
  <official_title>Therapeutic Nipple Areola Skin-sparing Mastectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pr. G. HOUVENAEGHEL, Institut Paoli Calmettes, Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multicentric, single arm study with a sequential design using the exact
      conditional Poisson test.

      The primary objective of this prospective study is to evaluate whether selected breast
      carcinoma patients could be treated with nipple sparing mastectomy (NSM) with an acceptable
      low local recurrence rates.

      450 patients will be included over a period of 4 years and will be followed for a 5 years
      period (twice a year).

      All patients must have a complete preoperative evaluation (bilateral mammography, bilateral
      breast ultrasonography +/- MRI), and a histopathological diagnostic proof of carcinoma
      (invasive or in situ, all histopathological types, first treatment or relapse).

      The study procedure is represented by nipple areola skin-sparing mastectomy followed by
      immediate breast reconstruction.

      After surgery, early and late complications, including specific complications (suffering of
      the nipple-areolar complexe and suffering of the skin flaps), will be evaluate.

      An esthetic evaluation (by patient and clinician) and a quality of life evaluation will be
      realized throughout the study.

      A complementary study, prospective, non-interventional, will be proposed to patients who
      will benefit from the same surgical technique (NSM) followed by immediate reconstruction,
      but in the context of preventive surgery (prophylactic surgery for patients mutated or high
      genetic risk). The aim of this complementary study, which will include a maximum of 60
      patients, is to evaluate associated morbidity in prophylactic NSM.

      Data will be collected over a 3 months period after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence rate.</measure>
    <time_frame>9 years.</time_frame>
    <description>Annual incidence of local recurrence defined by the number of local recurrences (skin, thoracic wall and nipple) among the patient years of follow-up..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early and late complications</measure>
    <time_frame>9 years.</time_frame>
    <description>Early and late complications will be evaluated using NCI toxicity scale version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free Survival.</measure>
    <time_frame>9 years.</time_frame>
    <description>Disease-free survival is the period between the date of origin and date of the first event as defined below, or date of latest news (Censored Data).
The events included in the definition of disease-free survival are local recurrence, lymph node metastases, contralateral locations, distant metastases, second breast cancer and death from any causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis Free Survival.</measure>
    <time_frame>9 years.</time_frame>
    <description>Metastasis free survival is defined as the time from inclusion until the date of metastasis recurrence or the date of the latest news (Censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival.</measure>
    <time_frame>9 years</time_frame>
    <description>Overall survival is defined as the time from inclusion until the date of death or the date of the latest news (Censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aesthetic evaluation.</measure>
    <time_frame>9 years.</time_frame>
    <description>The aesthetic evaluation will be realized by both the surgeon and the patient using to the Licket scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life.</measure>
    <time_frame>9 years.</time_frame>
    <description>The quality of life will be evaluated according to the Breast-Q questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Invasive or in situ breast carcinoma.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nipple sparing mastectomy</intervention_name>
    <description>Standardized surgical procedure by :
Nipple sparing mastectomy with nipple core histopathology.
Immediate breast reconstruction (flap and/or implant).
+/- lymph node evaluation (sentinel node procedure or axillary dissection).</description>
    <arm_group_label>Invasive or in situ breast carcinoma.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with invasive breast carcinoma stage T1 or T2 and / or in situ (any
             histological type) proved on histopathological diagnosis.

          -  Patient with an indication of total mastectomy.

          -  Patient without preoperative indication of adjuvant radiotherapy according to
             regional and / or national guidelines.

          -  Disease located more than 2 cm from the nipple after complete clinical and radiologic
             breast evaluation (mammography, ultrasound +/- MRI).

          -  Initial breast cancer or recurrence.

          -  Patient wishing to receive immediate breast reconstruction.

          -  WHO performance &lt; or = 2.

          -  Patient older than 40 years.

          -  For patients of childbearing age, use an effective contraceptive methods for the
             duration of the study.

          -  For patients of childbearing potential, negative pregnancy test available before
             inclusion.

          -  Patient affiliated to a social health insurance in France.

          -  Patient who signed informed consent before enrollment in the study and before any
             specific procedure for the study.

        Exclusion Criteria :

          -  Positive node on physical examination or proved by cytology.

          -  Combination of 2 predictive factors of postoperative radiotherapy : macroscopic
             multifocal, grade 2 or 3, vascular emboli, overexpressed HER2 (human epidermal growth
             factor receptor-2), triple negative (Estrogen Receptor, Progesterone Receptor and
             HER2 negative).

          -  Neoadjuvant treatment for the current disease.

          -  Patient with bilateral breast cancer.

          -  Paget disease.

          -  T3 or T4 carcinoma.

          -  Metastatic breast cancer (disease staging realized according to national or regional
             guidelines).

          -  Breast hypertrophy requiring a nipple support flap.

          -  Nursing or pregnant woman.

          -  Patient participating in any other interventional clinical study.

          -  Any psychological, familial, geographic or social situation not to comply with
             medical monitoring and/or procedures in the study protocol.

          -  Patient protected by law.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eva JOUVE, Md.</last_name>
    <phone>05 31 15 53 63</phone>
    <phone_ext>+33</phone_ext>
    <email>jouve.eva@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion FOURNIER, Md.</last_name>
      <phone>05 56 33 32 37</phone>
      <phone_ext>+33</phone_ext>
      <email>m.fournier@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marion FOURNIER, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine LOUSTALOT, Md.</last_name>
      <phone>03 45 34 80 72</phone>
      <phone_ext>+33</phone_ext>
      <email>CLoustalot@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine LOUSTALOT, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Levallois-Perret</name>
      <address>
        <city>Levallois-perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre LEDUEY, Md.</last_name>
      <phone>01 47 59 55 12</phone>
      <phone_ext>+33</phone_ext>
      <email>alexandre.leduey@ihfb.org</email>
    </contact>
    <investigator>
      <last_name>Alexandre LEDUEY, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia REGIS, Md.</last_name>
      <phone>03 20 29 59 59</phone>
      <phone_ext>+33</phone_ext>
      <email>c-regis@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Claudia REGIS, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas CARRABIN, Md.</last_name>
      <phone>04 78 78 28 28</phone>
      <phone_ext>+33</phone_ext>
      <email>nicolas.carrabin@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas CARRABIN, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles HOUVENAEGHEL, Pr.</last_name>
      <phone>04 91 22 33 33</phone>
      <phone_ext>+33</phone_ext>
      <email>Houvenaeghelg@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles HOUVENAEGHEL, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Du Cancer de Montpellier</name>
      <address>
        <city>Montepellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marian GUTOWSKI, Md.</last_name>
      <phone>04 61 61 85 81</phone>
      <phone_ext>+33</phone_ext>
      <email>marian.gutowski@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marian GUTOWSKI, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Clementville</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile ZINZINDOHOUE, Md.</last_name>
      <phone>04 67 58 08 72</phone>
      <phone_ext>+33</phone_ext>
      <email>cecile.zinzindohoue@le-mis.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile ZINZINDOHOUE, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ap-Hp - Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael ATLAN, Dr.</last_name>
      <phone>01 56 01 70 00</phone>
      <phone_ext>+33</phone_ext>
      <email>drmichaelatlan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michael ATLAN, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agathe CROUZET, Md.</last_name>
      <phone>02 32 08 22 16</phone>
      <phone_ext>+33</phone_ext>
      <email>agathe.crouzet@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Agathe CROUZET, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Mathilde</name>
      <address>
        <city>Rouen</city>
        <zip>76175</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc BARON, Md.</last_name>
      <phone>02 76 64 10 55</phone>
      <phone_ext>+33</phone_ext>
      <email>marc.baron@clinique-mathilde.fr</email>
    </contact>
    <investigator>
      <last_name>Marc BARON, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste Chirurgicale</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine BOUTEILLE, Md.</last_name>
      <phone>04 77 81 82 36</phone>
      <phone_ext>+33</phone_ext>
      <email>C1BOUTEILLE@mutualite-loire.com</email>
    </contact>
    <investigator>
      <last_name>Catherine BOUTEILLE, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INSTITUT DE CANCEROLOGIE DE L'OUEST - Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoire BRILLAUD-MEFLAH, Md.</last_name>
      <phone>02 40 67 99 00</phone>
      <phone_ext>+33</phone_ext>
      <email>victoire.brillaud-meflah@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Victoire BRILLAUD-MEFLAH, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva JOUVE, Md.</last_name>
      <phone>05 31 15 53 63</phone>
      <phone_ext>+33</phone_ext>
      <email>jouve.eva@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Eva JOUVE, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric MARCHAL, Md.</last_name>
      <phone>03 83 59 84 51</phone>
      <phone_ext>+33</phone_ext>
      <email>f.marchal@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric MARCHAL, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>December 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Invasive carcinoma</keyword>
  <keyword>In situ carcinoma</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Nipple areola</keyword>
  <keyword>Reconstruction</keyword>
  <keyword>Local recurrence</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
